Related Experiment Video

Updated: Sep 2, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Left Atrial Appendage Occlusion, A Misnomer?: Where Do We Go From Here?

David R Holmes1, Trevor J Simard1, Ammar M Killu1

  • 1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Mayo Clinic Proceedings
|August 6, 2022
PubMed

Insights

The left atrial appendage (LAA) is a major stroke source in atrial fibrillation. LAA occlusion aims to prevent clots, but incomplete closure remains a challenge, prompting new device and technique development.

Area of Science:

  • Cardiology
  • Medical Devices
  • Thrombosis Research

Background:

  • The left atrial appendage (LAA) is a primary source of thromboembolism, particularly ischemic stroke, in patients with nonvalvular atrial fibrillation.
  • Over 90% of ischemic strokes in this population are linked to LAA thrombus.
  • Oral anticoagulation is standard but often contraindicated or discontinued, necessitating alternative therapies.

Purpose of the Study:

  • To investigate the challenges and ongoing developments in left atrial appendage (LAA) occlusion therapies.
  • To explore the reasons behind incomplete LAA closure with current surgical and transcatheter methods.
  • To identify emerging strategies for improving LAA closure efficacy.

Main Methods:

  • Review of current literature on LAA occlusion techniques (surgical and transcatheter).
  • Analysis of factors contributing to incomplete LAA closure.
  • Examination of novel device designs and deployment techniques under development.
  • Exploration of alternative leak closure strategies.

Main Results:

  • Incomplete LAA closure is a frequent issue with existing surgical and transcatheter occlusion methods.
  • The underlying causes and clinical significance of incomplete closure are not fully understood.
  • Multiple innovative approaches are being developed to enhance LAA closure rates and effectiveness.

Conclusions:

  • Despite advancements, achieving complete LAA closure remains a significant challenge in preventing thromboembolism.
  • Further research and technological innovation are crucial to optimize LAA occlusion therapies.
  • New strategies focusing on device design, deployment, and leak closure are essential for improving patient outcomes.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.8K

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
30
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
193
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
37
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
38
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
40